COCP News and Press, Cocrystal Pharma Inc. From 03/29/23

2023-03-29 08:28:15 ET Cocrystal Pharma press release ( NASDAQ: COCP ): FY GAAP EPS of -$4.77. Cocrystal reported unrestricted cash of $37.1 million as of December 31, 2022 Net cash used in operating activities for 2022 was $21.4 million. The Company reported...

BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities. “This is an eventful time for C...

BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit Conference being held on Wednesday, March 29, 2023 at 10:30 a.m. Eastern time. “This ...

BOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community events: Noble Capital Markets ’ J.P. Morgan Healthcare Conference Takeaways...

Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal Pharma" or "the Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicati...

BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC- 42344 in its Phase 1 study. CC-42344 is a broad-spectrum antiviral for the treatme...

Affirms plans to report topline P hase 1 results in 2022 and to initiate P hase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with CC-42...

BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending dose portions of the ongoing Phase 1 study. CC-42344 is a br...

Cocrystal Pharma press release ( NASDAQ: COCP ): Q3 GAAP EPS of -$0.70 misses by $0.21 . Cocrystal reported unrestricted cash of $42.1 million as of September 30, 2022 compared with $58.7 million as of December 31, 2021. Shares +4.38% PM. For further deta...

Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and seasonal influenza A; remains on track to report topline results in 2022 Announced oral presentation of CC-42344 Phase 1 influenza A data at ...